Todd C. Davis is a co-founder, Managing Partner, Chairman of the Portfolio Management Committee and member of the Investment Committee at HCR. He brings particular expertise in the commercial, operational and licensing aspects of potential investments, and is responsible for the management of HCR’s existing portfolio of over $1 billion.
Mr. Davis has been involved in over $2 billion in healthcare principal investments including sourcing, conducting due diligence, and closing more than $1 billion in royalty financings. In addition, Mr. Davis coordinates the firm’s public relations activities.
Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners.
Prior to beginning his principal investment career in 2001, Mr. Davis held various sales and product management roles at Abbott Laboratories and worked in business development, operations and licensing at Elan Pharmaceuticals. Mr. Davis holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard Business School. He currently serves on the boards of Suneva Medical, Ligand Pharmaceuticals, AcuFocus and TearScience.